• Advocacy News

     
     
     
    Type Size
     

    Hart Health Strategies Health Policy Briefing

    May 13, 2019

    SCAI shares the weekly Health Policy Briefing update from Hart Health Strategies. This week they report that the House of Representatives unanimously passed two Bills aimed at lowering drug costs. The Orange Book Transparency Act of 2019 (H.R. 1503) would codify current requirements to list drug substance patents, drug product patents, and method-of-use patents, as well as other patents at the Food and Drug Administration’s (FDA) discretion. The Purple Book Continuity Act of 2019 (H.R. 1520) would codify the requirement to list the name of the biologic, date of licensing, studies necessary for biosimilar applications, and withdrawal or suspension of licensure in the Purple Book, the reference guide to biological products. To learn more.